PBS policy has become a 'crash or crash through' fixation on pricing and savings with decision-makers grabbing what they can while hoping to minimise the damage in the form of unintended consequences for patients. It is a case study of how not to manage a public health program.
These issues and the process are further evidence of a system under significant strain
October 11, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
Taking a stake is not the same as spectating investor risk and expecting a benefit
September 10, 2026 - - Latest News -
Artificial intelligence in HTA has arrived, kind of, but nobody was thinking of this
September 10, 2026 - - Latest News -
Melbourne oncologist takes the reins at Australia's private cancer physicians body
September 10, 2026 - -
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
September 10, 2026 - - Latest News -
Which is it? The two perspectives on patient input compounded by the lack of transparency
September 10, 2026 - - Latest News
